Compare Unilever plc (UL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unilever plc vs State Street SPDR S&P Biotech ETF — how do they compare? Unilever plc trades at $62.22 (market cap $131.63B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Unilever plc is far larger — about 13× State Street SPDR S&P Biotech ETF's market cap, and Unilever plc pays a 3.43% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Unilever plc for 112 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UL | XBI | |
|---|---|---|
Market Cap | $131.63B | $10.11B |
Volume | 2,978,741 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $74.59 | $169.55 |
52-Week Low | $55.05 | $104.99 |
Typical Hold Time | 112 Days | 38 Days |
Enterprise Value | $156.65B | — |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unilever (UL) trades at $61.98, up 1.64% with a bullish technical signal despite recent earnings misses. The company shows strong profitability with 18.32% net margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is mixed with 24% buy ratings amid ongoing business restructuring including the planned McCormick food division sale.
UL offers defensive exposure with emerging market growth potential but faces execution risks from portfolio streamlining. The stock presents moderate valuation (P/E 21.59) with cash flow stability, though recent earnings underperformance and regulatory scrutiny on the McCormick deal warrant caution for near-term investors.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
